FY2018 EPS Estimates for Pfizer, Inc. Decreased by Jefferies Group (PFE)
Pfizer, Inc. (NYSE:PFE) – Investment analysts at Jefferies Group reduced their FY2018 EPS estimates for shares of Pfizer in a research report issued to clients and investors on Thursday. Jefferies Group analyst J. Holford now anticipates that the biopharmaceutical company will post earnings of $2.77 per share for the year, down from their prior forecast of $2.83. Jefferies Group currently has a “Neutral” rating and a $39.00 target price on the stock. Jefferies Group also issued estimates for Pfizer’s FY2019 earnings at $2.85 EPS, FY2020 earnings at $2.92 EPS and FY2021 earnings at $3.23 EPS.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The business had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same period last year, the company posted $0.64 EPS. The business’s revenue was down 1.9% on a year-over-year basis. TRADEMARK VIOLATION NOTICE: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/30/fy2018-eps-estimates-for-pfizer-inc-decreased-by-jefferies-group-pfe.html.
PFE has been the subject of a number of other reports. ValuEngine upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Friday, October 6th. Morgan Stanley raised shares of Pfizer from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $35.00 to $39.00 in a report on Wednesday, September 20th. Barclays PLC set a $38.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, October 11th. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a report on Tuesday, October 3rd. Finally, BMO Capital Markets reissued a “buy” rating and issued a $37.00 price objective on shares of Pfizer in a report on Thursday, September 14th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $38.32.
Shares of Pfizer (NYSE:PFE) traded down 0.885% during trading on Monday, hitting $35.285. 3,726,738 shares of the company’s stock were exchanged. The company has a 50-day moving average of $35.81 and a 200-day moving average of $33.90. The company has a market cap of $209.85 billion, a P/E ratio of 25.812 and a beta of 1.00. Pfizer has a 12-month low of $29.83 and a 12-month high of $36.78.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 3.60%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.
In related news, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the transaction, the insider now owns 151,474 shares of the company’s stock, valued at approximately $5,074,379. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Sally Susman sold 38,230 shares of the business’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the completion of the transaction, the insider now directly owns 145,649 shares of the company’s stock, valued at approximately $5,097,715. The disclosure for this sale can be found here. Insiders have sold a total of 464,521 shares of company stock valued at $15,813,961 in the last ninety days. Corporate insiders own 0.06% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Altfest L J & Co. Inc. increased its stake in shares of Pfizer by 67.0% during the 2nd quarter. Altfest L J & Co. Inc. now owns 107,278 shares of the biopharmaceutical company’s stock valued at $3,603,000 after acquiring an additional 43,024 shares during the last quarter. Sphera Funds Management LTD. purchased a new stake in shares of Pfizer during the 1st quarter worth about $13,342,000. Searle & CO. grew its holdings in shares of Pfizer by 92.7% during the 1st quarter. Searle & CO. now owns 80,052 shares of the biopharmaceutical company’s stock worth $2,739,000 after purchasing an additional 38,500 shares during the period. Cadence Bank NA grew its holdings in shares of Pfizer by 1.4% during the 2nd quarter. Cadence Bank NA now owns 99,962 shares of the biopharmaceutical company’s stock worth $3,358,000 after purchasing an additional 1,428 shares during the period. Finally, Insight 2811 Inc. grew its holdings in shares of Pfizer by 3.7% during the 1st quarter. Insight 2811 Inc. now owns 9,324 shares of the biopharmaceutical company’s stock worth $319,000 after purchasing an additional 329 shares during the period. 69.01% of the stock is owned by institutional investors.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.